EPS Innovative Medicine (Japan) Limited is currently engaged in the business management and support of group companies and the promotion of our research department. Specific drug candidates/technologies that we own, and their business details are as follows.
- EPS Innovative Medicine (Japan) Limited manages and supports the business of FEF Pharmaceutical Co., Ltd., which is conducting clinical development with the aim of obtaining marketing authorization as a licensee of drug candidates/technologies originated by academia.
- EPS Innovative Medicine (Japan) Limited manages and supports the business of EPD Co., Ltd., aiming to create value of brown fat-cell introduction technology, originated by academia, as a licensee.
- Based on the idea that the septic IgA affects not only allergic diseases but also defense against the new coronavirus, its R&D Center is focusing on its significance and pursuing the possibility of sublingual vaccines.
For more information,
please feel free to contact us from below.